TG Therapeutics develops and sells BRIUMVI, a treatment for multiple sclerosis, to physicians and patients. TGTX reports earnings on Mon, Nov 2, 2026. In the past 30 days there were 1 dark pool print.
Earnings
Earnings calendar →Analyst Ratings & Price Targets
Analyst Ratings →| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Sep 1 | HC Wainwright & Co. | Target raised | Buy | |
| Aug 7 | JP Morgan | Maintained | Buy | |
| Jul 27 | B. Riley Securities | Maintained | Buy | |
| Jul 13 | HC Wainwright & Co. | Target raised | Buy | |
| Jul 7 | B of A Securities | Maintained | Sell |
Whale Options Flow
90DNo whale options trades in TGTX in the last 90 days.
Dark Pool
30DAI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether TGTX is in one of them and how their past TGTX trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered TGTX in an article yet. Here's the latest on the wider market.
TGTX Congress Trades
All congress trades →
| Person | Type | Amount | Traded | Filed | Delay |
|---|---|---|---|---|---|
| Donald J TrumpExecutive branch | Sell | $1K – $15K | Jul 29, 2026 | Sep 22, 2026 | 55 d |
| Donald J TrumpExecutive branch | Sell | $1K – $15K | May 15, 2026 | Jul 1, 2026 | 47 d |
| Donald J TrumpExecutive branch | Buy | $15K – $50K | Mar 4, 2025 | May 14, 2026 | 436 d |
| Donald J TrumpExecutive branch | Buy | $50K – $100K | Feb 26, 2025 | May 14, 2026 | 442 d |
| Christopher JacobsR · NY | Sell (partial) | $1K – $15K | Sep 8, 2020 | Nov 6, 2020 | 59 d |
Members of Congress and senior officials report trades up to 45 days later, as dollar ranges. Filings show a trade happened, not why. Not investment advice.
About TG Therapeutics
TG Therapeutics is a biotechnology company that develops and sells treatments for diseases driven by B cells, with its main focus on multiple sclerosis. Its approved product, BRIUMVI, is a monoclonal antibody given as an infusion lasting about an hour every 24 weeks to adults with relapsing forms of multiple sclerosis. Its customers include physicians and patients in the United States, and a commercial partner sells the treatment in several other countries. The company is based in Morrisville, North Carolina.
- Headquarters
- New York, NY
- Website
- tgtherapeutics.com ↗